Reasons to Retain Hims & Hers Stock in Your Portfolio for Now

Hims & Hers (HIMS) is driving growth through expanded weight-loss offerings, international expansion surging 17-fold, and AI-enabled care improving engagement and reducing costs. However, the company faces headwinds from gross margin compression due to lower-margin product mix, negative free cash flow from working capital requirements, and regulatory uncertainty around FDA peptide therapy approvals. The stock holds a Zacks Rank #3 (Hold) rating.